Comparative Study
. 2007 Oct 1;25(28):4506-7; author reply 4508.
doi: 10.1200/JCO.2007.13.0401.
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
- PMID: 17906218
- DOI: 10.1200/JCO.2007.13.0401
Item in Clipboard
Comparative Study
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
J Clin Oncol.
.
No abstract available
Comment on
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452677 Clinical Trial.
Similar articles
-
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.Pancreas. 2011 Jan;40(1):170-1. doi: 10.1097/MPA.0b013e3181e4242d. Pancreas. 2011. PMID: 21160383 No abstract available.
-
Finding clinical meaning in cancer data.J Natl Cancer Inst. 2007 Dec 19;99(24):1832-5. doi: 10.1093/jnci/djm283. Epub 2007 Dec 11. J Natl Cancer Inst. 2007. PMID: 18073370 No abstract available.
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.Invest New Drugs. 2011 Aug;29(4):694-9. doi: 10.1007/s10637-010-9386-6. Epub 2010 Jan 27. Invest New Drugs. 2011. PMID: 20107864 Clinical Trial.
-
Pancreatic cancer: an update.Curr Oncol Rep. 2007 May;9(3):170-6. doi: 10.1007/s11912-007-0018-z. Curr Oncol Rep. 2007. PMID: 17430687 Review.
-
Novel advances in pancreatic cancer treatment.Expert Rev Anticancer Ther. 2008 Jun;8(6):993-1002. doi: 10.1586/14737140.8.6.993. Expert Rev Anticancer Ther. 2008. PMID: 18533808 Review.
Cited by
-
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.Br J Cancer. 2015 Mar 17;112(6):971-6. doi: 10.1038/bjc.2015.55. Br J Cancer. 2015. PMID: 25688740 Free PMC article. Clinical Trial.
-
Approving molecularly targeted drugs: different approval processes for cytotoxic agents.Int J Clin Oncol. 2016 Oct;21(5):1004-1013. doi: 10.1007/s10147-016-0980-2. Epub 2016 Apr 22. Int J Clin Oncol. 2016. PMID: 27105626
-
Personalization of chemotherapy for metastatic pancreatic cancer.Clin Med Insights Case Rep. 2014 Jul 24;7:59-61. doi: 10.4137/CCRep.S14478. eCollection 2014. Clin Med Insights Case Rep. 2014. PMID: 25093005 Free PMC article.
-
Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.Curr Oncol. 2013 Apr;20(2):e90-e106. doi: 10.3747/co.20.1223. Curr Oncol. 2013. PMID: 23559890 Free PMC article.
-
End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy.Cancer. 2008 Dec 15;113(12 Suppl):3540-7. doi: 10.1002/cncr.23946. Cancer. 2008. PMID: 19058149 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
